Gene: AFP ×
Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 174
Gene Symbol: AFP
AFP 		0.050 Biomarker phenotype BEFREE Receiver operating curves were drawn to estimate the best AFP reduction cut off for differentiating between responders (CR plus PR) from non-responders (PD). 31483691 2019
Entrez Id: 174
Gene Symbol: AFP
AFP 		0.050 GeneticVariation phenotype BEFREE AFP response was classified as follows: complete response, normalization of AFP; partial response, > 50% decrease from baseline; stable disease, - 50 to + 30% change from baseline; or progressive disease, > 30% increase from baseline. 31250181 2019
Entrez Id: 174
Gene Symbol: AFP
AFP 		0.050 Biomarker phenotype BEFREE Multivariate analysis showed that SATI (low- vs. high-SATI: HR, 2.065; 95% CI, 1.187-3.593; <i>p</i>=0.010), serum albumin (<3.5 vs. ≥3.5 g/dL; HR, 2.007; 95% CI, 1.037-3.886; <i>p</i>=0.039), serum alpha-fetoprotein (<20 vs. ≥20 ng/mL; HR, 0.311; 95% CI, 0.179-0.540; <i>p</i><0.001), and Modified Response Evaluation Criteria in Solid Tumors assessment (complete response+partial response+stable disease vs. progressive disease; HR, 0.392; 95% CI, 0.221-0.696; <i>p</i>=0.001) were indicated as independent prognostic factors for OS. 30100754 2018
Entrez Id: 174
Gene Symbol: AFP
AFP 		0.050 Biomarker phenotype BEFREE Although AFP criteria and mRECIST showed significantly prognostic strata for CR, PR, SD, and PD after chemoembolization (P < .001 for both), some overlap in radiologic PD survival curves was observed. 30396842 2018
Entrez Id: 174
Gene Symbol: AFP
AFP 		0.050 Biomarker phenotype BEFREE Among the evaluable patients with stages II-IV, 48 (98%) achieved complete remission after chemotherapy ± surgery, one (IT + AFP, stage IV) had progressive disease. 28449306 2017